R
Roderick H. Dashwood
Researcher at Texas A&M University
Publications - 212
Citations - 13186
Roderick H. Dashwood is an academic researcher from Texas A&M University. The author has contributed to research in topics: Cancer & Histone deacetylase. The author has an hindex of 62, co-authored 202 publications receiving 12101 citations. Previous affiliations of Roderick H. Dashwood include Lanzhou University & Texas A&M Health Science Center.
Papers
More filters
Journal ArticleDOI
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis
TL;DR: In a recent study, the authors found that intake of cruciferous vegetables has been associated with lower risk of lung and colorectal cancer in some epidemiological studies, but evidence of an inverse association between consumption of these vegetables and breast or prostate cancer in humans is limited and inconsistent.
Journal ArticleDOI
A Novel Mechanism of Chemoprotection by Sulforaphane: Inhibition of Histone Deacetylase
TL;DR: Findings suggest that SFN may be effective as a tumor-suppressing agent and as a chemotherapeutic agent, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.
Journal ArticleDOI
Multi-targeted prevention of cancer by sulforaphane.
TL;DR: Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables and is especially high in broccoli and broccoli sprouts, with an emphasis on the possible chemoprevention mechanisms.
Journal ArticleDOI
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice
TL;DR: Results provide the first evidence for HDAC inhibition by SFN in vivo and imply that such a mechanism might contribute to the cancer chemoprotective and therapeutic effects of SFN, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.
Journal ArticleDOI
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells
TL;DR: This work shows that addition of 15 microM SFN also inhibited HDAC activity by 40, 30 and 40% in BPH-1, LnCaP and PC-3 prostate epithelial cells, respectively, and suggests a novel approach to chemoprotection and chemotherapy of prostate cancer through the inhibition of HDAC.